Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | MMP3 | P08254 | 5/20 | 0.41 |
| ▸ | MMP8 | P22894 | 4/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | CETP | P11597 | 3/20 | 0.40 |
| ▸ | MMP1 | P03956 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21804792 | 0.76 | PPARD (0.40) | MAPTMAPK1 | |
| SCHEMBL17533540 | 0.75 | MAPT (0.39) | MAPTMAPK1FOLH1HSD17B10 | |
| SCHEMBL27725067 | 0.74 | L3MBTL1 (0.55) | L3MBTL1MMP3MMP8MMP9PPARA | |
| SCHEMBL27725065 | 0.74 | L3MBTL1 (0.55) | L3MBTL1MMP3MMP8MMP9PPARA | |
| SCHEMBL1907332 | 0.74 | PPARA (0.58) | L3MBTL1MMP3PPARAMMP1MAPT | |
| SCHEMBL1759186 | 0.74 | POLB (0.46) | L3MBTL1MMP3MMP8MMP9CETP | |
| SCHEMBL29520381 | 0.74 | FOLH1 (0.48) | L3MBTL1PPARACETPMAPTMAPK1 | |
| SCHEMBL6293054 | 0.73 | L3MBTL1 (0.50) | L3MBTL1PPARAMAPK1SYKPPARG | |
| SCHEMBL15684087 | 0.73 | L3MBTL1 (0.51) | L3MBTL1MMP3MMP8MMP9PPARA | |
| SCHEMBL14243701 | 0.73 | L3MBTL1 (0.51) | L3MBTL1MMP3MMP8MMP9PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166087-B | Screening agent and use thereof | 恩多塞特公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE INC (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE INC (US) | 2021-10-21 | — | — | US | disclosed |
| CN-113166087-A | Shielding agent and application thereof | 恩多塞特公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020061293-A1 | SHIELDING AGENTS AND THEIR USE | ENDOCYTE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323985-A1 | SHIELDING AGENTS AND THEIR USE | PSMA6, PSMA2, PSMA1 | L3MBTL1 723/4885MMP3 2307/4885MMP8 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.